Novel diuretics
US4261985A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Nov 14, 1979 |
| Grant date | Apr 14, 1981 |
| Priority date | — |
| Expiry date | Nov 14, 1999 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An advantageous diuretic action by excretion of water, sodium and chloride ions, with reduced excretion of potassium ions, is effected by combined administration of a 19-oxygenated steroid compound of the pregnane series of the formula ##STR1## wherein R.sub.a represents a hydrogen atom, and PA1 R.sub.b represents an .alpha.-oriented lower alkanoylthio group, or PA1 R.sub.a and R.sub.b together represent a carbon-carbon bond or an .alpha.- or .beta.-oriented methylene radical, PA1 R represents a free hydroxymethyl group or a hydroxymethyl group etherified by a lower alkyl or esterified by a lower alkanoyl; or represents a carboxyl group or a lower alkoxycarbonyl group, and PA1 R.sup.2 represents a hydrogen atom or the acyl radical Ac of a carboxylic acid, as the aldosterone-antagonising component A on the one hand, and, on the other hand, of a conventional diuretic which is unspecific in respect of electrolyte excretion, e.g. a diuretically effective derivative of benzothiadiazine, benzenesulfonamide, phenoxyacetic acid, benzofuran-2-carboxylic acid or 2,3-dihydrobenzofuran-2-carboxylic acid, as component B. The two components A and B can be administered separately or together as a…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.